

PHG Update: September 30, 2021

Dear Valued Providers

We want to be a resource to our Premier Health Group Independent providers. We will continue to provide clinical and operational updates as they become available to support the provider community.

In this issue, providers will find an updated order form, information regarding payment penalties for non-compliance with authorization requirements, and information on the SARS CoV2 spike protein antibody test and the nucleocapsid antibody test.

Please feel free to contact us directly at (937) 499-7441 if you have any questions.

Premier Health Group

#### IN THIS ISSUE

Updated Monoclonal Antibody Infusion Therapy Center Order Form


Anthem Payment Penalties for Non-Compliance with Authorization Requirements

SARS CoV-2 Antibody


## Updated Monoclonal Antibody Infusion Therapy Order

The monoclonal antibody infusion therapy order has been updated. The form is updated on a regular basis. To ensure, you have the most recent version of the form, please go to PremierHealth.com and view the order. Below are the specific steps to take to ensure the most recent form is being used:

1. Go to [www.premierhealth.com](https://www.premierhealth.com)
2. Locate search bar at top of screen and enter “covid order”



3. Select the link to the order set



## Anthem Payment Penalties for Non-Compliance with Authorization Requirements

As of **October 1, 2021**, Anthem will be applying a 100% payment penalty for non-compliance with authorization requirements. This policy applies to outpatient elective diagnostic tests, outpatient elective surgical procedures, and inpatient elective surgical procedures. This penalty will be applied to both the provider and hospital.

Anthem commercial is Premier Health's largest volume commercial payer. Between January and June 2021, more than 14,500 elective diagnostic tests and surgical procedures were provided to Anthem commercial members at Premier Health facilities.

Your compliance with our current operational practice of scheduling buffers of at least four days for diagnostic testing and at least seven days for surgical procedures will allow the Premier pre-certification staff time to ensure prior authorization is obtained and securing payment for both providers and the hospital. In the event a prior authorization is not obtained before the scheduled service date, we ask you to reschedule any non-emergent test or procedure. In the event of a denial by the insurance company, we ask that you cancel the non-emergent test or procedure and work with the pre-certification team to provide the clinical information needed to get the procedure approved for a future date. Your assistance in these processes will ensure our success as an organization.

If you have questions about Anthem's policy or hospital processes related to prior authorization, please contact Amanda Ricci at **(937) 499-5267**.

We appreciate your collaboration on this important issue.

## SARS CoV-2 Antibody

CompuNet Clinical Laboratories is providing the following information about the two SARS CoV2 antibody tests on the market today: **SARS CoV2 Spike Protein Antibody test** and the **Nucleocapsid Antibody test**.

The SARS CoV2 Spike Protein Antibody test detects an immune response resulting from a recent or prior infection and/or an immune response to a COVID spike protein vaccine. This is a semi-quantitative test that aids in indicating an immune response resulting from a recent or prior infection and/or an immune response to a COVID spike protein vaccine. It is recommended to test four weeks after possible infection or 4 weeks after the final dose of Pfizer or Moderna Vaccine or 4 weeks after the single dose Johnson and Johnson/Janssen Vaccine. Results will be reported as negative or positive along with a number that generates a positive result at 50 - >25,000 AU/mL. Per the manufacturer of the assay, the results of this assay should not be interpreted as an indication or degree of immunity or protection from infection. Please note that the Spike Protein assay will not differentiate antibody response due to infection or vaccination.

**Due to restrictive reimbursement guidelines and medical necessity limitations, the Spike Protein Antibody test is currently only available through CompuNet's Direct Access Testing program\*. The cost of the test is \$65 and is available at all CompuNet patient service centers.**

The Nucleocapsid Antibody test is a qualitative test that detects the presence of antibodies indicating an immune response resulting from a recent or prior infection. The test has limited use -- various studies have indicated that nucleocapsid antibodies tend to become undetectable sooner than spike protein antibodies. This test would not be expected to detect an immune response to a spike protein vaccine. Natural infections produce both nucleocapsid and spike proteins antibodies. **Because of its limited use, the Nucleocapsid Antibody test will be discontinued effective October 1, 2021.**